Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Insulin growth factor 2 contributes to adipose stem cell-derived exosome mediated angiogenesis against hind-limb ischemia injury.

Li X., Chen Q., Li R., Shao B., Cui DS., Ren SH.

Animal Study on Peripheral Artery Disease, published in Cytokine (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cytokine (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40592129
DOI
10.1016/j.cyto.2025.156984

Abstract (original English)

Critical limb ischemia is a severe stage when hypoperfusion occurs in patients with lower extremity arteriosclerotic obliterans. Exosomes have emerged as a key therapeutic agent for lower extremity ischemia. However, how these exosomes take effects on ischemic limb is still unknown. Insulin-like growth factor II (IGF2) is a key protein responsible for guiding angiogenesis. Mouse ischemic limb was injected with phosphate buffer saline (PBS), exosomes from murine adipose-derived stem cells (ADSC-Exo) and IGF2-specific knockout of ADSC-Exo (IGF2 -/- -Exo), respectively, then blood flow was detected at 21 days after injection. The level of dynamic limb movement and impairment were assessed by ambulatory impairment and tissue damage scores. Laser Doppler imaging was performed to measure the blood flow of the ischemic limbs. Molecular biology experiment is performed to investigate the mechanism of ADSC-Exo mediated limb protection against ischemia injury. Compared with the untreated group, ADSC-Exo injection significantly promoted blood perfusion of ischemic hind limbs, while knockout of IGF2 weakened the therapeutic effect of the ADSC-Exo. The fluorescence intensity of CD31 + in the IGF2 -/- -Exo-treated group was lower than that in the ADSC-Exo group. Tubular structures of endothelial cells in ADSC-Exo-treated group were significantly more than those in PBS-treated group, while end

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsIschemiaHindlimbNeovascularization, PhysiologicMiceInsulin-Like Growth Factor IIExosomesStem CellsMice, KnockoutMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research